

## Heinz Läubli, MD PhD

### 1. Personal Information



Assistant Professor (non-tenured)  
Specialist in General Internal Medicine  
and Medical Oncology, FMH  
OrcID: 0000-0002-8910-5620

University Hospital Basel  
Petersgraben 4, CH-4031 Basel

---

### 2. Education

03/19 Venia Legendi, Faculty of Medicine, University of Basel, Switzerland  
02/19 Research visit, Cell Therapy Program, Stanford University, CA, USA (D. Miklos & C. Mackall)  
2015 Swiss Board Certification in Medical Oncology, FMH  
2013 Swiss Board Certification in General Internal Medicine, FMH  
2005-2008 PhD Thesis at the Institute of Physiology, University of Zürich (L. Borsig, 8. December 2008)  
2004-2005 ECFMG certification, United States Medical Licensing Examinations  
2005 MD Thesis at the Institute of Physiology, University of Zürich (E.G. Berger, 21. April 2005)  
1998-2004 Medical studies at Universities of Zürich and Lausanne (Diploma 30. October 2004)

### 3. Employment History

Since 05/20 Assistant Professor for Cellular Cancer Immunotherapy, University of Basel and Senior Attending Physician (Leitender Arzt), Oncology, University Hospital Basel  
Since 06/19 Research group leader Department of Biomedicine, Laboratory for Cancer Immunotherapy, University of Basel  
Since 01/16 Attending physician, Division of Oncology and Head of Glycobiology Research (Project Leader), Cancer Immunology Laboratory, University Hospital Basel  
05/14-12/15 Clinical fellow, Division of Oncology (C. Rochlitz) and Project Leader, Cancer Immunology Laboratory (A. Zippelius), University Hospital Basel  
05/12- 04/14 Postdoctoral Researcher (A. Varki), Department of Cellular and Molecular Medicine, University of California, San Diego, USA  
05/10-04/12 Resident, Department of Internal Medicine, Division of Hematology and Oncology, University Hospital, Basel (J. Schifferli, J. Passweg, C. Rochlitz)  
12/08-04/10 Resident, Department of Internal Medicine, See-Spital, Horgen

### 4. Institutional Responsibilities, Leadership

- Senior attending physician Medical Oncology, University Hospital Basel: Head of Neuro-Oncology unit, Co-Head of Dermato-Oncology unit, Co-Head of Immunotherapy Network
- Head of Phase I Unit, Oncology University Hospital Basel
- Group Leader, Department of Clinical Research, University of Basel
- Head of Laboratory for Cancer Immunotherapy, Department of Biomedicine, University of Basel, Laboratory for Cancer Immunotherapy
- Head of the tumor-infiltrating lymphocyte (TIL) program for solid tumors at the University Hospital Basel

- Head of GMP development and production, Innovation Focus Cell Therapy, University Hospital Basel
- Head of the Steering Committee of the Flow Cytometry Core at the Department of Biomedicine

#### **5. Approved research projects (5 years)**

- SNSF Project Grant, (310030\_215237/1), 2023-2026
- Innovation Focus Cell Therapy (Co-Applicant), University Hospital, 2021-2026
- Cancer Research Switzerland, (KFS-5239-02-2021R), 2021-2024
- Innosuisse grant (42408.1 IP-LS), 2020-2022
- SNSF Project Grant, (310030\_184720/1), 2019-2022
- Swiss Cancer Research, Treatment of relapsed glioblastoma patients with targeted immunoliposomes, 2017-2019
- Research Grant, Krebsliga Beider Basel, 2017
- Goldschmidt-Jacobson Stiftung, Targeting Siglec receptors in cancer, 2016

#### **6. Supervision of junior researchers**

- Postdocs: Anne Bärenwaldt PhD, Marta Trüb PhD, Natalia Rodrigues Mantuano PhD, Michela Manni PhD, Luana Guerra PhD,
- MD, MD PhD students: Philip Schmassmann MD, David König MD, Nikolai Rohner, Benjamin Müller
- PhD students: Michal Stanczak, Jinyu Wang, Andreas Zingg, Ronja Wieboldt, Michael Sandholzer, Johanna Nimmerjahn
- Mentoring Basel: David König MD, Sarah Dräger MD

#### **7. Teaching activities**

- Lecturer, Department of Pharmaceutical Sciences, University of Basel
- Several Lectures for Medical Students at the University Hospital Basel
- Lecturer University of Fribourg, Switzerland
- Organizer: Projekte Clinical Medicine (PCM, Moderne Onkologie – Von der Diagnose zur Therapie)

#### **8. Editorial activities, board memberships**

- Associate editor for the *Journal for Immunotherapy of Cancer (JITC)*, *Pharmacology*, and *Frontiers in Immunology*
- Ad hoc reviewer for: *Nature*, *Nature Communications*, *Cancer Discovery*, *Cancer Cell*, *Cell Reports*, *Journal of Immunology*, *Cancer Research*, *New England Journal of Medicine*, *Cancer Immunology Immunotherapy*, *Glycobiology*, Dutch Cancer Society, *Blood*, *Frontiers in Immunology*
- Palleon Pharmaceuticals, GlycoEra (both Scientific Advisory Board member)
- Co-Founder of Singenavir Ltd

#### **9. Professional memberships**

- Swiss Medical Association, FMH; Schweizerische Gesellschaft für Medizinische Onkologie, SGMO; American Society of Clinical Oncology, ASCO; Society for the Immunotherapy of Cancer, SITC; Society for Glycobiology; American Association for Cancer Research, AACR; Schweizerische Arbeitsgemeinschaft für klinische Krebsforschung, SAKK

#### **10. Organization of Conferences**

- Organization of Cell Therapy Symposium, November 2023
- Co-Organizer of the EUCC (European Cancer Center) Meeting 2017 in Basel
- Organization of the symposium: 'Treatment of brain metastasis' at the University Hospital Basel, September 2018

#### **11. Prizes**

- Annemarie-Karrasch Preis 2020